MICRON BIOMEDICAL

Elizabeth Holmberg’s more than 30 years of financial leadership experience spans biotechnology, medical device, and pharmaceutical companies. Her expertise is in consistently helping organizations secure capital, build scalable infrastructure, negotiate transformative strategic partnerships, and prepare for commercialization and public markets. Prior to Micron Biomedical, she served as Chief Financial Officer of Third Pole Therapeutics, where she built the company’s finance and human resources functions and helped secure more than $100 million in financing including major pharmaceutical partnerships. She also negotiated a global commercialization and distribution agreement valued at more than $500 million, demonstrating her ability to structure partnerships that accelerate market entry and maximize value creation. Previously, Holmberg served as Chief Financial Officer of Ikaria, where she led their spin-out in 2008, securing $275 million in debt financing to support the company’s growth and IPO readiness. Ikaria was subsequently acquired by Mallinckrodt in 2015 for $2.3B. Earlier in her career, she held a senior finance leadership role at INO Therapeutics (which became Ikaria) where she supported the successful commercial launch of INOmax®–a critical intervention for newborns suffering from Hypoxic Respiratory Failure. “Disrupting access to healthcare requires a new approach to manufacturing, storing, transporting and administering medicines and vaccines that are currently injected and I am honored to step into this role during such a critical juncture when we are poised to significantly accelerate the availability of Micron’s products,” said Holmberg. “I am committed to building on Micron’s strong financial foundation to drive continued success as we expand our pipeline, scale up manufacturing and bring life-changing innovations to patients that immediately improve health outcomes, operational efficiencies and patient experiences.”

Dr. McAllister has 25 years of experience developing medical devices and pharmaceutical dosage forms including microneedle-based patch technologies. He received a BS from Rensselaer Polytechnic Institute and a PhD from the Georgia Institute of Technology, both in chemical engineering. Dr. McAllister leads Micron’s R&D activities, overseeing the development of Micron’s microneedle patch technology and serving as the principal investigator on several grants and contracts including from the Gates Foundation and the CDC. Prior to co-founding Micron, Dr. McAllister was the technical head of Valeritas’ microneedle development program and co-inventor of their lead product, V-Go, the first insulin pump marketed to the large Type 2 diabetes market. He has over 30 US patents issued or pending and has served as a consultant for a number of medical device companies. Prior to Valeritas, he was a Senior R&D Engineer, Diabetes Division, at Johnson & Johnson.

Mr. Henry has over 20 years of research, product development, and project management experience in the microneedle and medical device fields including overall product development responsibilities at Porex Surgical, now owned by Stryker, a company that develops, manufactures, and sells craniofacial implants to surgeons in five surgical specialties. He received a BS from the University of Technology of Compiègne (France) and an MS from the Georgia Institute of Technology, both in bioengineering, as well as an MBA from the Georgia Institute of Technology. Mr. Henry has 8 US patents issued or pending and has worked on microneedles projects at Georgia Tech and Micron for over 10 years.